Skip to main content
. 2024 Jul 30;17(8):e13900. doi: 10.1111/cts.13900

TABLE 2.

Summary of adverse events.

Study Pitavastatin (n = 18) Atorvastatin (n = 18) Rosuvastatin (n = 29) Pravastatin (n = 18) Simvastatin (n = 20) Fluvastatin (n = 19) Total (n = 122)
Any adverse event 4 [3] 15 [11] 18 [14] 7 [5] 16 [10] 17 [10] 77 [53]
Pemafibrate alone 2 [1] 6 [4] 3 [3] 2 [2] 2 [2] 3 [2] 18 [14]
Statin alone 1 [1] 6 [6] 6 [6] 2 [2] 6 [4] 7 [6] 28 [25]
Combination 1 [1] 3 [3] 9 [7] 3 [3] 8 [6] 7 [6] 31 [26]
Adverse event leading to discontinuation 0 0 3 [3] 0 0 0 3 [3]
Pemafibrate alone 0 0 0 0 0 0 0
Statin alone 0 0 1 [1] a 0 0 0 1 [1]
Combination 0 0 2 [2] b , c 0 0 0 2 [2]
Death or serious adverse event 0 0 0 0 0 0 0
Severe adverse event 0 0 1 [1] b 0 0 0 1 [1]
Moderate adverse event 1 [1] d 0 2 [2] a , e 0 0 0 3 [3]
Mild adverse event 1 [1] 5 [4] 14 [11] 1 [1] 7 [5] 9 [7] 37 [29]
Laboratory test abnormal 2 [2] 10 [9] 1 [1] c 6 [4] 9 [6] 8 [5] 36 [27]
Adverse event for which a causal relationship with study drugs could not be ruled out 1 [1] 8 [6] 0 3 [2] 10 [7] 12 [9] 34 [25]

Data are presented as the number of events [the number of participants who had at least one event].

a

Musculoskeletal chest pain.

b

Sciatica.

c

Blood creatine phosphokinase increased.

d

Gastroenteritis.

e

Viral upper respiratory tract infection.